The robust electrochemical detection of a Parkinson's disease marker in whole blood sera

Bryan, Thomas; Liu, Xiang; Forsgren, Lars; Morozova‐Roche, Ludmilla A.; Davis, Jason J.

doi:10.1039/c2sc21221h

Cited by 74 publications

(74 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,11 In more recent work we have demonstrated that these capabilities can be incorporated into both the analysis of real patient samples and the simultaneous detection of multiple markers. 11,[17][18][19][20][21] Faradaic EIS assays are almost exclusively based on analysing the parameter of charge transfer resistance (R ct ) obtained by fitting the acquired current signal to a Randles equivalent circuit (see SI Figure 1 for details) , 22,23 while non-faradaic analyses most typically use modulus of the impedance (|Z|), double layer capacitance (C dl ) or phase (ϕ) as sampling functions. 9,[24][25][26][27] In both approaches a phenomenological model based either on an equivalent circuit 28 or continuum scheme derived from microscopic Poisson-Nernst-Plank continuum equations (using conventional or alternative approaches for diffusional activity) [29][30][31] can be applied from which physical parameters can be extracted.…”

Section: Introdutionmentioning

confidence: 99%

Immittance Electroanalysis in Diagnostics

et al. 2014

Self Cite

View full text Add to dashboard Cite

Impedance derived electroanalytical assays are inherently spectroscopic (frequency resolved) and potentially exceedingly sensitive indicators of interfacial change (such as target binding at an appropriate receptor). We introduce here the use of a portfolio of mathematically derived immittance functions and related components, capable, from the same raw data sets, of enabling increased assay sensitivity and markedly shorter assay times in comparison to traditional impedance analyses. The methodology, applied herein to faradaic (redox probe amplified) and non-faradaic assays, requires no equivalent circuit analysis or prior assumption of response. Its focus is to optimize analytical potency and to enable the user to select and apply the most frequency-optimized reporter of interfacial change and to, thereafter, run rapid (optimized) analyses at single frequencies.

show abstract

Section: Introdutionmentioning

confidence: 99%

Immittance Electroanalysis in Diagnostics

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nanotechnology has been used for both diagnosis and therapeutics of the PD in advance medical studies worldwide [14][15][16]. For PD diagnosis, several nanobiosensors have been developed so far based on the quantification of different biomarkers of PD such as dopamine [17,18], alpha-synuclein protein [19], homovanilic acid [20] and even PD-related genetic mutation [21]. Nanobiosensors comprise the advantages of using nanomaterials and nanostructures in biosensors, especially electrochemical nanobiosensors.…”

Section: Introductionmentioning

confidence: 99%

A highly sensitive miR-195 nanobiosensor for early detection of Parkinson’s disease

Aghili

Nasirizadeh

Divsalar

et al. 2017

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Early detection of Parkinson's disease (PD), as a dangerous neurodegenerative disease, is a key factor in the therapy or prevention of further development of this disease. We developed an electrochemical nanobiosensor for early detection of PD based on the quantification of circulating biomarker, miR-195. Exfoliated graphene oxide (EGO) and gold nanowires (GNWs) were used to modify the surface of screen-printed carbon electrode. A single-strand thiolated probe was designed for specific hybridization with target miRNA (miR-195), and doxorubicin was used as an electrochemical indicator for differential pulse voltammetry measurements. The results of scanning electron microscope imaging and cyclic voltammetry experiments confirmed the accuracy of the working electrode modification steps. The results of analytical performance nanobiosensor showed a high sensitivity of the biosensing with 2.9 femtomolar detection limit and dynamic range of 10.0-900.0 femtomolar. In addition, good selectivity for target miRNA over non-specific oligonucleotides (one and three base replacement in target miRNA, and non-complementary) was achieved. The results of real human serum analysis did not show any interference in the function of the biosensor. Based on the results, the miR-195 electrochemical nanobiosensor could be suggested for clinicians in the medical diagnosis of PD.

show abstract

“…EIS is widely used to validate the layer-by-layer deposition of materials to a sensor surface because it is a very powerful tool for surface interface characterization and detection of changes to biosensor surfaces (Bryan et al, 2012;Rushworth et al, 2014). Here, impedance measurements were performed at each stage of the assembly in 10 mM K4Fe(CN)6/K3Fe(CN)6 (1:1 ratio) in PBS pH 7 over a frequency range 40-40,000 Hz.…”

Section: Confirmation Of Biosensor Assembly By Eis and CVmentioning

confidence: 99%

Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor

Wang

Acha

Shah

et al. 2017

Biosensors and Bioelectronics

View full text Add to dashboard Cite

This study presents a novel approach based on a four-electrode electrochemical biosensor for the detection of tau protein -one of the possible markers for the prediction of Alzheimer's disease (AD). The biosensor is based on the formation of stable antibody-antigen complexes on gold microband electrodes covered with a layer of a self-assembled monolayer and protein G. Antibodies were immobilized on the gold electrode surface in an optimal orientation by protein G interaction. Electrochemical impedance spectroscopy was used to analyze impedance change, which revealed a linear response with increasing tau concentrations. The assay is fast (<1 h for incubation and measurement) and very sensitive. The limit of quantification for the full-length 2N4R tau protein is 0.03 pM, a value unaltered when the assay was processed in bovine serum albumin or human serum. This technology could be adapted for the detection of other biomarkers to provide a multiple assay to identify AD progression in a point of care setting.

show abstract

The robust electrochemical detection of a Parkinson's disease marker in whole blood sera

Cited by 74 publications

References 51 publications

Immittance Electroanalysis in Diagnostics

Immittance Electroanalysis in Diagnostics

A highly sensitive miR-195 nanobiosensor for early detection of Parkinson’s disease

Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor

Contact Info

Product

Resources

About